You need to be logged in to view this video
New regenerative biopharmaceutical products are now under clinical development to stimulate the body to heal itself. Promising clinical results in treating such diverse disorders from heart disease to degenerative brain diseases will be discussed.
Jack Jacobs
Zhittya Genesis Medicine, Inc.,
President and Chief Scientific Officer
Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations, as well as the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of biological chemistry at Merck and for 15 years worked with Mr. Daniel Montano as cardiovascular biotherapeutics' chief scientific officer. Dr. Jacobs oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease. He also oversaw the manufacturing of clinical lots of FGF-1 that were used in those clinical studies. Dr. Jacobs received a BS degree from Davidson College and a PhD in molecular biology from Washington University, St. Louis.
Trending Now
Filter By Category
Filter By Keywords
Loading...